Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2015

View Archived Issues

AmorChem licenses mucoadhesive nanoparticle technology from University of Waterloo

JDRF supports Janssen's disease interception approach to prevent onset of type 1 diabetes

Cidara Therapeutics completes financing round to support pipeline

Cipla's U.K. subsidiary enters into a joint venture with Cooper Pharma and PHI

DARPA awards contract to SRI Biosciences to discover synthetic polymer drugs

Novigenix acquires colon cancer blood test Colox

AC Immune receives MJFF grant to develop PET tracer for Parkinson's disease diagnosis

Clinigen opens global access program for ceftazidime/avibactam

Epitarget and IC Contrast complete merger

Promising data revealed on a novel Ebola vaccine candidate

Novavax begins phase I Ebola vaccine trial

Horizon Pharma submits IND application for Actimmune for Friedreich's ataxia

Shanghai Institute Materia Medica discloses new alpha1A-adrenoreceptor antagonists

Vernalis and Servier patent novel Bcl-2 inhibitors

Novartis reports new apelin receptor agonists

New FXIa inhibitors designed by Bayer

Capsule depolymerase EnvD shows efficacy in an inhalation model of anthrax

Scientists at Instituto Italiano di Tecnologia disclose FAAH inhibitors

FDA approves lenvatinib for thyroid cancer

First in vivo results presented of novel ricin and Shigatoxin trafficking inhibitors

Lassa fever recombinant vaccine shows enhanced immunogenicity in mice

FDA accepts NDA for Pfizer's abuse-deterrent formulation of oxycodone

FDA approves sNDA for rufinamide in Lennox-Gastaut syndrome in children aged 1-4 years

Novartis's LCZ-696 to receive FDA priority review for heart failure

N9-GP shows efficacy in pediatric hemophilia B patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...